Search Results
Your search for The ASCO P matches 3781 pages
Showing 2751 - 2800Adjuvant Chemotherapy in Early-Stage Non–Small Cell Lung Cancer Improves Overall Survival
The use of adjuvant chemotherapy in early-stage non–small cell lung cancer (NSCLC) patients improves overall survival and 5-year overall survival rates in patients with tumor sizes ranging from 3 to 7 cm. These findings were published by Morgensztern et al in the Journal of Thoracic...
ASCO Releases Clinical Practice Guideline on Metastatic Pancreatic Cancer
As reported in the Journal of Clinical Oncology by Davendra P. Sohal, MD, MPH, of Cleveland Clinic, and colleagues, ASCO has released a clinical practice guideline on the treatment of patients with metastatic pancreatic cancer. Recommendations are based on expert panel systematic review of the...
ASCO Releases Clinical Practice Guideline on Treatment of Locally Advanced, Unresectable Pancreatic Cancer
As reported by Edward P. Balaban, DO, of Penn State Hershey Cancer Institute, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on the treatment of locally advanced, unresectable pancreatic cancer. The recommendations are based on expert panel...
ASCO Value in Cancer Care Task Force
The Value in Cancer Care Task Force was established in 2007 to educate oncologists about the importance of discussing costs associated with recommended treatments, empower patients to ask questions about the anticipated costs of their treatment options, identify the drivers of the rising costs of...
SIRIUS Trial Heralds a New Era of Promise in Treating Resistant Myeloma
Multiple myeloma cells uniformly overexpress CD38.1 Daratumumab (Darzalex), a CD38-targeting human IgG1 kappa monoclonal antibody, has been evaluated in a series of phase I/II trials involving patients with relapsed or relapsed and refractory myeloma who have received at least two or more prior...
Prostate Cancer: Opinions Vary on Gleason Scores and Surgery
Diagnosis and treatment of prostate cancer have been the source of heated debate for decades, most of which has centered on the clinical value of the prostate-specific antigen (PSA) test. In 2012, the U.S Preventive Services Task Force (USPSTF) gave the PSA test a D grade, which discourages many...
2016 ASCO Annual Meeting Planning Committees
The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with nearly 30,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees and thank them for their time and...
PALOMA-3 Trial in HER2-Negative Metastatic Breast Cancer: Challenge of Moving Beyond Estrogen Receptor Positivity
Hormone receptor–positive breast cancer represents the largest therapeutic subgroup of the disease. The development of endocrine therapies has shaped the treatment paradigm for both advanced- and early-stage disease for decades.1 Still, despite their significant impact, advanced breast cancer...
Combined-Modality Therapy for Low-Grade Gliomas: Balancing Toxicity, Delivery Logistics, and Survival Benefit
Low-grade gliomas account for 15% of all primary brain tumors and represent a heterogeneous group of glial neoplasms. Although these tumors have been termed low-grade, this is a misnomer, especially for some grade II gliomas, which may exhibit a more aggressive behavior and variable natural...
Ovarian Suppression in Premenopausal Women With Estrogen Receptor–Positive Breast Cancer
Oophorectomy was the first proposed form of endocrine therapy for women with breast cancer. Over 100 years ago, Thomas Nunn reported a relationship between menopause and regression of breast cancer.1 This incited interest in the induction of menopause as an anticancer therapy, and in 1986, a...
Adjuvant Chemotherapy Improves Survival in Pancreatic Cancer
An adjuvant chemotherapy regimen improved overall survival in early-stage pancreatic cancer patients, in the large phase III European ESPAC-4 study reported at the 2016 ASCO Annual Meeting.1 The combination of gemcitabine and capecitabine almost doubled the 5-year survival rate, compared to...
Chemoradiotherapy Improves Survival in Patients Over Age 65 With Glioblastoma: A New Standard Option?
The combination of short-course radiotherapy and temozolomide followed by maintenance with temozolomide significantly improved survival compared with short-course radiotherapy alone in newly diagnosed elderly patients with glioblastoma, according to the results of a global cooperative group trial...
Additional 5 Years of Letrozole May Benefit Some Postmenopausal Women With Early-Stage Breast Cancer
Five years of aromatase inhibitor as upfront therapy or after tamoxifen is the current standard of care for postmenopausal women with early hormone receptor–positive breast cancer. A new trial suggests that extending aromatase inhibitor therapy with letrozole for an additional 5 years may improve...
Daratumumab Hits the Mark in Early Relapsed Multiple Myeloma
For relapsed or refractory multiple myeloma, daratumumab (Darzalex), combined with bortezomib (Velcade) and dexamethasone, reduced relapses by 61% in the phase III CASTOR study reported at the 2016 ASCO Annual Meeting.1 “The results are unprecedented in a randomized study comparing a novel...
Alan P. Venook, MD, and John Marshall, MD, on Metastatic Colorectal Cancer: Analysis of CALGB-SWOG 80405
Alan Venook, MD, of the University of California, San Francisco, and John Marshall, MD, of the Lombardi Cancer Center at Georgetown University, discuss the impact of primary tumor location on overall survival and progression-free survival in patients with advanced disease (Abstract 3504).
John P. Neoptolemos, MD, PhD, on Pancreatic Ductal Adenocarcinoma: Results of the ESPAC-4 Trial
John P. Neoptolemos, MD, PhD, of the University of Liverpool, discusses findings from this international phase III study of adjuvant combination chemotherapy: gemcitabine and capecitabine vs monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma (Abstract LBA4006).
ASCO 2016: Adding Capecitabine Chemotherapy to Gemcitabine Extends Survival After Pancreatic Cancer Surgery
For a more in-depth look at these data, as well as commentary, click here. A European phase III trial, one of the largest ever conducted in pancreatic cancer, showed that adding the oral drug capecitabine chemotherapy to gemcitabine prolongs survival without increased toxicity. Adjuvant...
External Validation of a Prediction Tool for Chemotherapy Toxicity in Older Patients With Cancer
Hurria et al validated a prediction tool for chemotherapy toxicity in cancer patients aged ≥ 65 years in an external cohort, according to a report in the Journal of Clinical Oncology. The predictive model had been developed in a prior study in 500 patients. Study Details The study...
Recipients of the David A. Karnofsky Memorial Award and Lecture
David A. Karnofsky, MD, dedicated himself to the pursuit of scientific excellence and the investigation of more effective therapies for cancer for nearly 30 years, from the time he was a resident at the Collis P. Huntington Memorial Hospital for Cancer Research of Harvard University, until his...
With a Strong Personal Connection to His Patients, Stephen P. Hunger, MD, Strives for a Cure for All Children With Leukemia
Nationally regarded children’s cancer specialist Stephen P. Hunger, MD, was born and reared in South Windsor, a small suburb of Hartford, Connecticut. Dr. Hunger grew up in the mid-1960s and 1970s, and in his words, “South Windsor was a pretty homogeneous experience. There wasn’t really any ethnic...
Eribulin in Liposarcoma: A Closer Look at the Comparative Data
Sarcoma therapy is a challenge for oncologists. Soft-tissue sarcomas encompass more than 50 different histologies, resulting in limited familiarity of management for many treating physicians. In addition, there have been few available effective therapies. The phase III trial of eribulin (Halavan) ...
Atezolizumab in Previously Treated Advanced Urothelial Carcinoma
The recent study by Rosenberg et al in The Lancet—summarized in this issue of The ASCO Post—is a very important paper in the field of bladder cancer therapy.1 It is the first phase II trial in metastatic transitional cell carcinoma that demonstrates the single-agent activity of the...
ASCO Recognizes 2016 Recipients of FASCO Distinction
�� The Fellow of the American Society of Clinical Oncology (FASCO) distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Their efforts benefit ASCO, the specialty of oncology, and, most importantly, patients with cancer. The 2016...
AACR Inducts 2016 Class of Fellows of the AACR Academy
The American Association for Cancer Research (AACR) has announced its 11 newly elected Fellows of the AACR Academy. The AACR Academy serves to recognize and honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer. All...
Highlights From the 2016 AACR Annual Meeting
This year’s Annual Meeting of the American Association for Cancer Research (AACR) featured outstanding research in the field of cancer, as well as an inspiring talk by Vice President Joe Biden (see the May 10 issue of The ASCO Post). Here are some summaries of studies that warrant attention; they...
Maximizing Cancer Cure: How Do We Get There?
Is cancer really “curable,” and if so, how? For a “Cancer Dialogue” held during the 2016 American Association of Cancer Research (AACR) Annual Meeting, half a dozen stellar participants from the research, industry, regulatory, and advocacy communities convened to debate the topic. The ASCO Post was ...
Upfront Transplant Remains Standard of Care in Multiple Myeloma
Upfront autologous stem cell transplant remains the standard of care in patients with newly diagnosed multiple myeloma, even in the era of novel agents, according to a phase III study of the European Myeloma Network.1 “Our findings show that autologous stem cell transplant should remain the...
Site of Tumor Impacts Survival and Choice of Treatment in Metastatic Colorectal Cancer
In metastatic colorectal cancer, the anatomic location of the tumor within the colon appears to make a difference in overall survival as well as response to pivotal treatments, according to a retrospective analysis of the pivotal CALGB/SWOG 80405 (Alliance) trial.1 “While previous studies had...
ASCO 2016: Left- vs Right-Sided Primary Tumor Location Predicts Survival in Metastatic Colorectal Cancer
For a longer-form examination of these data, click here. A retrospective analysis from a large, federally funded clinical trial finds that the location of the primary tumor within the colon predicts survival and may help inform optimal treatment selection for patients with metastatic colorectal...
AATS 2016: Strategies for Increasing Survival In Soft-Tissue Sarcoma Patients With Lung Metastases Undergoing Resection
Up to 50% of patients with soft-tissue sarcoma develop lung metastases. Effective systemic therapies for metastatic soft-tissue sarcoma are currently limited; when possible, pulmonary metastasectomy is the preferred treatment. However, guidelines for the performance of pulmonary metastasectomy for...
AUA 2016: Cell-Cycle Progression Score Provides Significant Prognostic Information in Patients With Gleason Score < 7
Myriad Genetics announced results from a study of the prognostic information provided by its Prolaris test in patients with prostate cancer and a Gleason score < 7 at the 111th Annual Scientific Meeting of the American Urological Association (AUA) (Abstract MP02-20). Prolaris is a novel 46-gene ...
AUA 2016: Adjuvant Chemotherapy After Radical Prostatectomy May Benefit Men at High Risk for Relapse
Not all men with prostate cancer benefit from adjuvant chemotherapy after radical prostatectomy; however, African American men and men with a higher tumor stage may, according to a new U.S. Department of Veterans Affairs (VA) study (Abstract PI LBA 06) featured at the 111th Annual Scientific...
FDA Approves Cabozantinib in Patients With Renal Cell Carcinoma Who Have Received Prior Antiangiogenic Therapy
On April 25, 2016, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) tablets for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy. Cabozantinib is a dual tyrosine kinase inhibitor of MET and VEGFR2. The capsule...
Roundup of Ovarian Cancer Abstracts From 2016 SGO Annual Meeting on Women’s Cancer
At the 2016 Society of Gynecologic Oncology’s (SOG’s) Annual Meeting on Women’s Cancer, Thomas J. Herzog, MD, Clinical Director, University of Cincinnati (UC) Cancer Institute and Professor of Obstetrics and Gynecology at UC College of Medicine, provided commentary on several noteworthy ovarian...
ESTRO 2016: Failure to Publish Phase III Radiotherapy Trial Results Exposes Patients to Risks Without Providing Benefits for Others
Although the publication of results of clinical trials carried out in the United States within 12 months of their completion has been mandatory since 2007, a remarkably high number of phase III radiotherapy trials did not do so, according to new research presented at the European Society for...
FDA Approves Cabozantinib in Patients With Renal Cell Carcinoma Who Have Received Prior Antiangiogenic Therapy
On April 25, 2016, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) tablets for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy. Cabozantinib is a dual tyrosine kinase inhibitor of MET and VEGFR2. The...
Quality-of-Life Benefits of Contralateral Prophylactic Mastectomy May Be Too Small to Be Clinically Meaningful
Women diagnosed with breast cancer who chose contralateral prophylactic mastectomy reported improvement in psychosocial well-being and breast satisfaction, but “the magnitude of the effect may be too small to be clinically meaningful,” according to a study in the Journal of Clinical Oncology.1...
Supportive Care in the Older Adult With Cancer: What You Need to Know
The median age of patients at the first diagnosis of cancer in the United States is 65 years, and the majority of patients with cancer are older adults.1 As we have learned from previous articles in this series, older patients with cancer require more complex care. Older adults are more likely to...
Seven New Members Elected to Interurban Clinical Club
The historic Interurban Clinical Club has announced the election of seven new members. They were elected at the group’s 213th meeting on April 1 in New York and will be welcomed at the group’s next meeting in November 2016 in Philadelphia. James E. Bradner, MD: Staff Physician at Dana-Farber...
2016 Special Awards: Researchers and Scientists Recognized for Significant Contributions to Cancer Care
Researchers, patient advocates, and global oncology community leaders dedicated to enhancing cancer prevention, treatment, and patient care will be honored with ASCO’s highest honor, its Special Awards, during the 2016 ASCO Annual Meeting. Among this year’s awardees are a lung cancer luminary who...
Boswellia
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. We chose Boswellia for this issue because of its increasing use by patients with cancer....
Scott A. Armstrong, MD, PhD, to Lead Department of Pediatric Oncology at Dana-Farber Cancer Institute
Scott A. Armstrong, MD, PhD, has been named Chair of the Department of Pediatric Oncology at Dana-Farber Cancer Institute and the David G. Nathan Professor of Pediatrics at Dana-Farber Cancer Institute, Boston Children’s Hospital, and Harvard Medical School. He will also serve as Associate Chief of ...
Updates on Elotuzumab in Multiple Myeloma Show Persistence of Benefit
Studies presented at the 2015 ASH Annual Meeting bolstered support for elotuzumab (Empliciti) given in combination with lenalidomide (Revlimid) for the treatment of multiple myeloma. Elotuzumab is an immunostimulatory monoclonal antibody. It has a dual mechanism of action, directly activating...
Active Surveillance Has Become Standard Care for Men With Low-Risk Localized Prostate Cancer
Active surveillance has been increasingly adopted as a standard approach for men with Gleason score ≤ 6 localized prostate cancer, with major guidelines and consensus statements encouraging this approach,1 including a recently published guideline from Cancer Care Ontario (CCO),2 and endorsement of...
CDX2 in Stage II Colon Cancer: Ready for Prime Time?
In a recent issue of The New England Journal of Medicine, Dalerba et al published an impressive article describing a novel bioinformatics approach to identifying new prognostic and predictive biomarkers in patients with stage II and III colon cancer (see summary in this issue of The ASCO Post).1...
AACR 2016: Certain Oral Bacteria May Be Associated With Increased Pancreatic Cancer Risk
The presence of two species of bacteria linked to periodontal disease in the mouths of healthy individuals was associated with an increased risk of subsequently developing pancreatic cancer, according to research presented by Fan et al at the 2016 AACR Annual Meeting (Abstract 4350). ...
Novel Strategies Emerging for Triple-Negative Breast Cancer
Compelling hypotheses are emerging about the mechanisms driving triple-negative breast cancer, and they are driving drug development in this area, according to Joyce O’Shaughnessy, MD, Celebrating Women Chair of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center. She is also Medical...
More Guidelines, Uniformity in Radiation Therapy Needed Following Chemotherapy, Surgery in Breast Cancer
Wide variability exists in radiation treatment decisions following neoadjuvant chemotherapy and surgery for breast cancer, according to a review of the American College of Surgeons Oncology Group (ACOSOG) Z1071 trial. These findings were published by Haffty et al in the International Journal of...
Joan Massagué, PhD, to Receive 2016 Pezcoller Foundation–AACR International Award for Cancer Research
The 2016 Pezcoller Foundation-American Association for Cancer Research (AACR) International Award for Cancer Research will be presented to Joan Massagué, PhD, Director of the Sloan Kettering Institute and Alfred P. Sloan Chair at Memorial Sloan Kettering Cancer Center in New York, at the AACR...
Phase Ib/II Study Reports High Response Rates Seen With Addition of Cisplatin to Regimen for Advanced Pancreatic Cancer
The oncology research team at HonorHealth Research Institute in Scottsdale, Arizona, is spearheading a phase Ib/II trial that is demonstrating promising results with a novel regimen in patients with advanced pancreatic cancer. “The patients we are treating have advanced adenocarcinoma of the...
